Aim: To assess activity and safety of erythropoietin (EP) drugs in conservative chronic renal failure (CRF).
Material and methods: The antianemic effect of EP drugs, central and cardiac hemodynamics were studied in 28 CRF patients (mean blood creatinine 5.27 mg%) with renal anemia. In addition, arterial pressure was automatically measured within 24 hours and the CRF progression rate was assessed.
Results: Low-dose EP drugs injected subcutaneously rapidly produced antianemic and cardioprotective effects and may improve residual renal function.
Conclusion: Pathogenetically grounded and safe for patients with conservative CRF is a combination of low-dose subcutaneous EP drugs with hypotensive drugs (calcium antagonists, ACE inhibitors), loop diuretics and low-protein diet.